UK Home Office loosens restrictions on GW’s Epidyolex
The cannabinoid has been reclassified as a Schedule 5 medicine meaning that it can be dispensed more easily
Read More
Tag: Gastaut syndrome
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
